Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOIRAI first-line CLL/SLL trial of venetoclax combinations with MRD-guided versus fixed duration treatment
NL-OMON60968Phase 3Recruiting
- Sponsor
- University of Cologne
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, pirtobrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by University of Cologne. Primary endpoint: Progression-free survival. Started Dec 2025; status: recruiting.
02
Drugs
venetoclaxpirtobrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON60968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60968.